https://youtu.be/hjngeTK8uq8
For many years, the battle against canine arthritis has been a challenging one, with limited breakthroughs in treatment options. However, in 2023, the emergence of a groundbreaking therapy called Beransa, also known as bedinvetmab or Librela, brings new hope to dogs suffering from osteoarthritis.
This article delves into the details of Beransa, its effectiveness, dosage, potential human health risks, side effects, and cost, with a focus on how it is transforming the lives of our beloved furry companions.
Understanding Beransa (Beransa Dogs):
Beransa, also known as bedinvetmab or Librela outside of Australia, is a revolutionary treatment for canine arthritis. It works by neutralizing nerve growth factor (NGF), a key player in the perception of pain. As a monoclonal antibody, Beransa is designed to be highly specific in targeting NGF, offering the potential to alleviate pain effectively.
Effectiveness of Beransa:
Studies conducted by the parent company of Beransa have shown promising results. After one week of treatment, approximately one in six dogs experienced significant benefits, which increased to one in two after a month. However, it’s important to note that there is a significant caregiver placebo effect, so realistic expectations are crucial. Many dogs may require additional arthritis remedies alongside Beransa for optimal results.
Beransa Dosage and Frequency:
Beransa is administered via subcutaneous injection at a dose of 0.5 – 1 mg/kg, with vial sizes available to accommodate different dog weights. It is recommended to try at least two doses before determining its effectiveness. Beransa should not be used in breeding, pregnant, lactating dogs, or those under 12 months of age, as NGF is essential for foetal and juvenile development.
Human Health Risks:
Pregnant women, women trying to conceive, and breastfeeding women should exercise extreme caution to avoid accidental self-injection or needle stick injuries. It’s advisable for them not to participate in the administration of the injection. However, it’s essential to clarify that a dog treated with Beransa poses no risk to humans.
Beransa Side Effects:
While some dogs may experience localized reactions such as swelling and heat at the injection site, these occurrences are relatively rare. Hypersensitivity reactions are possible but appear more common in the feline version of this drug, Solensia. Monoclonal antibodies like Beransa are generally considered safer than traditional drugs like anti-inflammatories due to their minimal metabolism or detoxification requirements. Nevertheless, caution is recommended when using Beransa in dogs with liver or kidney disease until further research is available.
Combining Beransa with other medications and vaccination is generally considered safe. However, when multiple treatments are administered, identifying the cause of any adverse effects may become challenging.
Cost of Beransa:
In 2023, the cost of a single Beransa injection ranges from $100 to $130, depending on the required dosage. This places it in a similar price range as higher-priced anti-inflammatory drugs. While Beransa may not be a one-size-fits-all solution, it represents another valuable option for managing canine arthritis. In some cases, it can help maintain a dog’s quality of life when other treatments have fallen short or are deemed unsafe.
The Path Forward:
While Beransa or Librela may not be a cure-all for canine arthritis, it represents a significant step forward in providing relief and improving the quality of life for our beloved dogs. The development of monoclonal antibodies like Beransa brings us closer to addressing the ongoing challenges faced by arthritic dogs and their owners. It may offer more time to enjoy the companionship of our aging canine friends.
Powerful Success Stories: Real-Life Transformations with Beransa Dog’s
Discover firsthand accounts of dogs whose lives have been revitalized by Beransa. Watch these inspiring YouTube videos to witness the incredible impact of this groundbreaking arthritis treatment.
https://youtu.be/gdh1y2o5vYY?si=n4PG9Vqp0v4Mnjdo
Conclusion:
If you have a dog suffering from arthritis, consider discussing the potential benefits of Beransa with your veterinarian. While it may not be suitable for every dog, the positive impact it has had on many canine lives is undeniable. With a comprehensive understanding of Beransa, its benefits, and its limitations, you can make an informed decision about the best approach to improving your dog’s quality of life. Your furry friend deserves the best care, and Beransa might just be the solution they need.
References
Corral, M. J., Moyaert, H., Fernandes, T., Escalada, M., Tena, J. K. S., Walters, R. R., & Stegemann, M. R. (2021). A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Veterinary anaesthesia and analgesia, 48(6), 943-955 Full Text
Kronenberger, K. (2023). In dogs diagnosed with osteoarthritis, how safe and effective is long-term treatment with bedinvetmab in providing analgesia?. Veterinary Evidence, 8(1) Full Text
New veterinary chemical product containing a new veterinary active constituent: BERANSA Solution for Injection for Dogs containing bedinvetmab. For more information see page 18, APVMA Gazette No. 14, 12 July 2022.
